miridesap   Click here for help

GtoPdb Ligand ID: 8256

Synonyms: compound 52 [PMID 14998318] [8] | CPHPC | GSK2315698 | Ro 63-8695 [8]
PDB Ligand
Compound class: Synthetic organic
Comment: Miridesap (CPHPC) is reported as a chemical which depletes the glycoprotein serum amyloid P component (SAP) in mice [1] and humans [2]. Intellectual property for the use of CPHPC has been licensed to GlaxoSmithKline who have coded the compound GSK2315698. Structurally, CPHPC is a simplified form of a captopril dimer [8]. Mechanistically miridesap cross-links pairs of SAP molecules in serum forming complexes that are rapidly cleared from the body and disrupts SAP binding to amyloid fibrils and neurofibrillary tangles [3]. SAP is a drug target for the treament of neurodegenerative diseases (amyloidoses) [7].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 115.22
Molecular weight 340.16
XLogP -0.15
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OC(=O)C1CCCN1C(=O)CCCCC(=O)N1CCCC1C(=O)O
Isomeric SMILES OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O
InChI InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
InChI Key HZLAWYIBLZNRFZ-VXGBXAGGSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Nature, 468 (7320): 93-7. [PMID:20962779]
2. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN et al.. (2010)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Br J Haematol, 148 (5): 760-7. [PMID:20064157]
3. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL et al.. (2009)
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
Proc Natl Acad Sci USA, 106 (18): 7619-23. [PMID:19372378]
4. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C et al.. (2002)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Nature, 417 (6886): 254-9. [PMID:12015594]
5. Richards D, Millns H, Cookson L, Lukas MA. (2022)
An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
Orphanet J Rare Dis, 17 (1): 259. [PMID:35810311]
6. Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD et al.. (2018)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Sci Transl Med, 10 (422). [PMID:29298867]
7. Schmidt AF, Finan C, Chopade S, Ellmerich S, Rossor MN, Hingorani AD, Pepys MB. (2023)
Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disorders.
medRxiv, Preprint. DOI: 10.1101/2023.08.15.23293564 [PMID:37645746]
8. Wermuth CG. (2004)
Selective optimization of side activities: another way for drug discovery.
J Med Chem, 47 (6): 1303-14. [PMID:14998318]